NOVO NORDISK A/S |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 134.6 EUR | +0.13% |
|
+1.23% | +44.11% |
| 28/06 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
| 28/06 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
Business Summary
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sales per Business
| DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Diabetes and Obesity Care
92.6
%
| 156,412 | 88.4 % | 215,098 | 92.6 % | +37.52% |
Rare Disease
7.4
%
| 20,542 | 11.6 % | 17,163 | 7.4 % | -16.45% |
Sales per region
| DKK in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
United States
54.9
%
| 84,656 | 47.8 % | 127,534 | 54.9 % | +50.65% |
EMEA
21.9
%
| 44,236 | 25.0 % | 50,867 | 21.9 % | +14.99% |
Rest of the World
12.1
%
| 25,402 | 14.4 % | 28,078 | 12.1 % | +10.53% |
China
7.2
%
| 16,209 | 9.2 % | 16,687 | 7.2 % | +2.95% |
Canada
3.9
%
| 6,451 | 3.6 % | 9,095 | 3.9 % | +40.99% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 58 | 01/91/01 | |
| Director of Finance/CFO | 53 | 01/99/01 | |
Stephen Gough
CTO | Chief Tech/Sci/R&D Officer | - | 01/15/01 |
Marcus Schindler
CTO | Chief Tech/Sci/R&D Officer | 57 | 01/18/01 |
| Chief Operating Officer | 54 | 01/92/01 | |
| Chief Tech/Sci/R&D Officer | 54 | 01/99/01 | |
Daniel Bohsen
IRC | Investor Relations Contact | - | 01/20/01 |
Tania Sabroe
HRO | Human Resources Officer | 47 | 01/07/01 |
| General Counsel | - | - | |
Sergey Manelis
PRN | Corporate Officer/Principal | - | 13/20/13 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sylvie Grégoire
BRD | Director/Board Member | 62 | 19/15/19 |
Helge Lund
CHM | Chairman | 62 | 23/17/23 |
Martin MacKay
BRD | Director/Board Member | 68 | 01/18/01 |
Kasim Kutay
BRD | Director/Board Member | 59 | 23/17/23 |
Andreas Fibig
BRD | Director/Board Member | 62 | 01/18/01 |
Henrik Poulsen
BRD | Director/Board Member | 57 | 25/21/25 |
| Director/Board Member | 58 | 01/92/01 | |
Christina Law
BRD | Director/Board Member | 57 | 01/22/01 |
Thomas Rantzau
BRD | Director/Board Member | 52 | 22/18/22 |
| Director/Board Member | 59 | 24/22/24 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 10 | 1,075,000,000 | 0 | 0 | 70.22 % |
| Stock B | 1 | 3,386,519,207 | 3,133,044,416 ( 92.52 %) | 48,091,207 ( 1.420 %) |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
NOVO NORDISK A/S 1.45% | 49,118,207 | 1.45% | 6,629,209,828 $ |
NNIT A/S 17.50% | 4,375,000 | 17.50% | 68,770,275 $ |
INNATE PHARMA 12.14% | 9,817,546 | 12.14% | 26,964,577 $ |
Company contact information
Group companies
| Name | Category and Sector |
|---|---|
Novo Nordisk India Pvt Ltd.
 Novo Nordisk India Pvt Ltd. Medical/Nursing ServicesHealth Services Part of Novo Nordisk A/S, Novo Nordisk India Pvt Ltd. is a leading healthcare company founded in 1923 and headquartered in Denmark. The company is based in Bengaluru, India. Novo Nordisk's purpose is to drive change to defeat diabetes and other serious chronic diseases. |
Medical/Nursing Services
|
Velfærdsfonden for Novo Nordisk A/S
|
Investment Trusts/Mutual Funds
|
NNE A/S
 NNE A/S Engineering & ConstructionIndustrial Services Part of Novo Nordisk A/S, NNE A/S is a Danish company that supplies systems, consultancy and engineering services. The company is based in Soborg, Denmark. |
Engineering & Construction
|
World Diabetes Foundation
|
Investment Trusts/Mutual Funds
|
Novo Nordisk Health Care AG
 Novo Nordisk Health Care AG Pharmaceuticals: MajorHealth Technology Novo Nordisk Health Care AG engages in the production and distribution of chemical and pharmaceutical products as well as articles for diagnostic and therapeutic applications. It also specializes in the research in and development of products, therapeutic methods, and display techniques primarily used in the chemical, pharmaceutical, and diagnostic fields. The company was founded on August 10, 2000 and is headquartered in Zurich, Switzerland. |
Pharmaceuticals: Major
|
Novo Nordisk Finance (Netherlands) BV
|
Finance/Rental/Leasing
|
Novo Nordisk Region Europe A/S
 Novo Nordisk Region Europe A/S Financial ConglomeratesFinance Novo Nordisk Region Europe A/S holds ownership interests in other companies to undertake investment and financing activities. It offers service on an operational basis, including the placement of capital in companies and real estate. The company was founded September 14, 2001 and is headquartered in Bagsvaerd, Denmark. |
Financial Conglomerates
|
Sector
Sales per Business
Sales per region
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +55.32% | 82TCr | |
| -6.75% | 35TCr | |
| +13.56% | 31TCr | |
| +10.68% | 30TCr | |
| +16.57% | 24TCr | |
| +2.04% | 22TCr | |
| +13.31% | 22TCr | |
| +8.48% | 17TCr | |
| -2.81% | 16TCr |
- Stock Market
- Equities
- NOVO B Stock
- NOV Stock
- Company Novo Nordisk A/S
